Laura Stoppel - Jun 15, 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jun 15, 2022
Transactions value $
$0
Form type
4
Date filed
6/17/2022, 04:27 PM
Previous filing
Jun 30, 2021
Next filing
Jun 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Stock Option (right to buy) Award $0 +25K $0.00 25K Jun 15, 2022 Common Stock 25K $3.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.